Eli Lilly & Co. v. Medtronic, Inc.

1990-08-13

Headline: Court allows testing and FDA approval work on medical devices without patent liability, holding that the patent-law exemption covers device-related regulatory submissions and eases competitors’ premarket preparation.

Holding: The Court held that the patent-law exemption for testing and regulatory submissions covers making, using, or selling patented inventions when those activities are reasonably related to developing and submitting information to the FDA for device approval.

Real World Impact:

Allows companies to test and submit FDA device approval data without automatic patent liability.
May let competitors begin regulatory testing earlier, changing when rival devices reach the market.
Leaves final determination to lower courts to decide if specific testing qualifies for the exemption.

Topics: medical devices, patent infringement, FDA approval, regulatory testing

Summary

Background

In 1983 a drug company sued a medical-device maker after the device maker tested and marketed an implantable cardiac defibrillator that the company said infringed two patents. The device maker argued its testing and regulatory work were done to develop information for FDA approval under the Food, Drug, and Cosmetic Act, and so were protected by a patent-law exemption. The lower district court ruled for the patent holder; the Federal Circuit reversed, and the Supreme Court agreed to decide the legal meaning of the exemption.

Reasoning

The Court examined whether the exemption’s phrase “a Federal law which regulates the manufacture, use, or sale of drugs” refers only to drug-specific approval rules or to entire statutes like the FDCA that also contain device approval rules. Relying on the statute’s wording and on the overall structure of the 1984 Act—especially how its patent-term extension and noninfringement provisions relate—the Court concluded the exemption more naturally covers activities reasonably related to submitting information under the FDCA, including device approvals. The Court affirmed the Federal Circuit’s interpretation and remanded for the district court to decide whether the device maker’s activities actually met the exemption’s conditions.

Real world impact

The decision lets companies perform certain testing and submit regulatory data for medical devices without automatically being liable for patent infringement, if those activities are reasonably related to FDA approval. The ruling is an interpretive, not final factual, outcome: a later court must determine whether the specific conduct in this case qualifies. The ruling affects how firms prepare generic or competing devices and may change when rivals may lawfully begin regulatory testing.

Dissents or concurrances

A dissent argued the ordinary meaning of the statute limits the exemption to drugs, warning that device testing often directly depletes the patent holder’s market and thus should not be excused.